ASH 2018: Older Patients With Chronic Lymphocytic Leukemia See Better Outcomes With Ibrutinib Than Chemoimmunotherapy
But toxicities may pose a problem for some elderly patients
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.